All clinical BACE1-inhibitor trials for the treatment of Alzheimer's Disease (AD) have failed due to insufficient efficacy or side effects like worsening of cognitive symptoms. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.